Analysts fell to the sidelines weighing in on Moderna (MRNA – Research Report) and Twist Bioscience (TWST – Research Report) with neutral ratings, indicating that the experts ...

Biotechnology company Moderna (NASDAQ:MRNA) reported Q2 CY2025 results exceeding the market’s revenue expectations, but sales ...

Moderna (MRNA) skyrocketed to fame during the pandemic, delivering one of the first mRNA-based Covid-19 vaccines and quickly ...

The U.S. health secretary ordered an end to new mRNA development efforts just after UTMB published new research showing its ...

Canadian doctors and scientists say Robert F. Kennedy Jr.'s defunding of mRNA vaccine research and development projects will ...

Moderna Inc. shares are selling off Wednesday, after the Trump administration took aim at the science behind the ...

Despite a net loss, Moderna Inc (MRNA) showcases resilience with significant cost cuts, new FDA approvals, and a robust cash ...

The U.S. health department is canceling or scaling back 22 BARDA-backed mRNA projects worth nearly $500 million, shifting ...

In a report released today, Mani Foroohar from Leerink Partners maintained a Sell rating on Moderna, with a price target of $18.00. The company’s shares opened today at $28.20. Take advantage of ...

Kennedy’s $500M cut to mRNA funding puts startups at risk and imperils one of life sciences’ few leasing bright spots.

Federal regulators are caught between old-guard conservatives who demand continued mRNA funding, Rep. Massie's demand to ...

Moderna had said earlier this year it expects operating costs to be between $4.7 billion and $5 billion for 2027. MRNA stock, ...